Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Arterra Bioscience SpA ( (IT:ARBS) ) is now available.
Arterra Bioscience reported unaudited revenues of about €1.6 million for the first quarter of 2026, up 22.21% from the same period in 2025, underscoring solid growth in its biotech-driven cosmetic and related activities. The company’s services segment declined 13.72% to €162,000, while sales of cosmetic raw materials surged 28.14% to roughly €1.46 million, confirming this line as the key growth engine.
Chief executive Maria Gabriella Colucci said the revenue performance aligns with the company’s commercial development strategy in cosmetic raw materials and matches internal forecasts. Management noted that the strength of orders already acquired supports a positive view for the current year, suggesting continued momentum in Arterra’s core cosmetic ingredient business and reinforcing its positioning within the cosmetic biotech supply chain.
More about Arterra Bioscience SpA
Arterra Bioscience S.p.A. is an Italian green biotech company focused on research and development in biotechnologies, applying living organisms such as bacteria, yeasts, and plant and animal cells to create enabling products and processes. Listed on Euronext Growth Milan since 2019, it operates across cosmetics, agriculture and nutraceuticals, and collaborates with partners including Isagro, Intercos and their Vitalab joint venture in skin care, personal hygiene and functional make-up.
Average Trading Volume: 8,700
Technical Sentiment Signal: Buy
Current Market Cap: €19.51M
See more insights into ARBS stock on TipRanks’ Stock Analysis page.